Full Press Release Details
AmpliPhi Biosciences Provides Corporate
and Strategic Update
14, 2017) - AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on
the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced its progress in
2017 and near-term strategic goals and initiatives.
2017 Corporate Highlights
Potential Milestones and Initiatives for the First Half of
"AmpliPhi has made tremendous progress throughout 2017,"
said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences. "To date, under the expanded access program, we have dosed seven patients
in dire need, who were suffering from serious and life-threatening infections and were not responding to antibiotic therapies.
We look forward to presenting topline results in early 2018. We have set a goal of dosing approximately 20 additional patients
during the first half of 2018. We continue the dialogue with the FDA and key thought leaders in the infectious disease community
regarding design of Phase 2 and registrational clinical studies of our bacteriophage therapies."
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a clinical-stage biotechnology
company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi's
lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are
included on the WHO's 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance
as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt
biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been
shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.
Forward Looking Statements
Statements in this press release that
are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include, without limitation, statements regarding: AmpliPhi's plan to present
topline results in early 2018 for the seven patients dosed with AB-SA01 or AB-PA01; AmpliPhi's plan to dose approximately
20 additional patients with its bacteriophage therapies during the first half of 2018; AmpliPhi's plan to present data from
approximately 25 expanded access clinical cases to the FDA in mid-2018 and potentially initiate a Phase 2 or registrational clinical
trial as early as the second half of 2018; and the potential benefits of phage therapy and the potential use of bacteriophages
to treat bacterial infections, including infections that do not respond to antibiotics or are associated with biofilms. Words such
as "believe," "anticipate," "plan," "expect," "intend," "will,"
"may," "goal," "potential" and similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could
cause actual results to differ materially from those indicated in these forward-looking statements are risks and uncertainties
associated with AmpliPhi's business and financial condition and the other risks and uncertainties described in AmpliPhi's
Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC, and AmpliPhi's subsequent filings
with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi
undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of
AmpliPhi Biosciences
David Schull or Maggie Beller